Elevance Health, Inc. (NYSE:ELV) Targets High Growth Amid Healthcare Innovations

Font: Financial Modeling Prep  • Mar 10, 2026

• Ann Hynes from Mizuho Securities sets a price target of $350 for Elevance Health, Inc. (NYSE:ELV), indicating a potential upside of approximately 23.81%.
• The company showcased its strategies at the Barclays 28th Annual Global Healthcare Conference, reflecting confidence in its market position and future growth.
• Elevance Health's stock has experienced volatility, with a yearly high of $458.75 and a low of $273.71, showcasing the dynamic nature of the healthcare sector.

Elevance Health, Inc. (NYSE:ELV) is a prominent player in the healthcare industry, providing a range of health benefits and services. The company is known for its innovative approach to healthcare solutions, aiming to improve health outcomes for its members. Elevance competes with other major healthcare providers, striving to maintain its position in a competitive market.

On March 10, 2026, Ann Hynes from Mizuho Securities set a price target of $350 for ELV. At that time, the stock was trading at $282.68, suggesting a potential upside of approximately 23.81%. This optimistic outlook reflects confidence in Elevance's strategies and market position, as highlighted by the recent Barclays 28th Annual Global Healthcare Conference.

During the conference, Elevance Health shared its strategies and insights into the healthcare industry. This event is crucial for companies like Elevance to present their developments and future plans. The stock price of $282.68, with a recent increase of 1.31% or $3.66, indicates positive market sentiment following the conference.

ELV's stock has shown volatility, with a trading range between $280.92 and $290.55 during the day. Over the past year, the stock has experienced a high of $458.75 and a low of $273.71. This fluctuation highlights the dynamic nature of the healthcare sector and the challenges companies face in maintaining stable growth.

Elevance Health's market capitalization is approximately $62.39 billion, reflecting its significant presence in the industry. With a trading volume of 2,496,868 shares on the NYSE, the stock remains actively traded, indicating strong investor interest and confidence in the company's future prospects.